# Talquetamab

Source: https://onco.cc/drugs/talquetamab/  
OnCo record `talquetamab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Talquetamab is the first drug against GPRC5D, a second myeloma target used after BCMA therapies stop working; taste and skin side effects are its signature.

## Summary

Talquetamab is a humanised IgG4 GPRC5DxCD3 bispecific antibody and the first drug against GPRC5D, a receptor expressed on plasma cells and on keratinised tissue. In MonumenTAL-1 the ORR was about 73% at both the weekly and biweekly doses, including about 65% in patients after prior T-cell redirection, showing that a second target works after BCMA therapy stops. Accelerated approval followed in August 2023 after at least 4 prior lines. Dysgeusia (72%), skin toxicity (67%) and nail disorders (54%) are frequent, cytokine release syndrome was grade 3 or higher in only 2%, and infection rates are lower than with BCMA agents. Combinations with teclistamab (RedirecTT-1, ORR about 80% with extramedullary disease) and daratumumab (TRIMM-2) are in phase 3 (MonumenTAL-3, -5 and -6). It opened a second target after BCMA in myeloma, at the cost of taste and skin effects.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: Talvey
- Modality: Bispecific T-cell engager (GPRC5D×CD3)
- Mechanism: Humanised IgG4 GPRC5D×CD3 bispecific; GPRC5D is expressed on plasma cells and keratinised tissue.
- Approvals: US 2023: Relapsed/refractory myeloma after ≥4 lines (accelerated)
- Dosing: Subcutaneous; Step-up then 0.4 mg/kg weekly or 0.8 mg/kg every 2 weeks
- Toxicity (grade 3+): Cytokine release syndrome 2%

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Talquetamab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Talquetamab

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Plasma cell leukaemia](https://onco.cc/cancers/plasma-cell-leukaemia/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/), [GPRC5D](https://onco.cc/targets/gprc5d/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi](https://onco.cc/trials/nct05455320/), [A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez](https://onco.cc/trials/nct06208150/), [A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma](https://onco.cc/trials/nct06550895/), [A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind](https://onco.cc/trials/nct06577025/), [A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal](https://onco.cc/trials/nct05552222/), [A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct04586426/), [A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events](https://onco.cc/trials/nct06500884/), [MonumenTAL-1](https://onco.cc/trials/monumental-1/)
- pairings: [BCMA-directed therapy → GPRC5D-directed therapy](https://onco.cc/pairings/bcma-then-gprc5d/)
- key papers: [MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response](https://onco.cc/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/), [MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-majestec-1-teclistamab-nejm-2022/), [MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma](https://onco.cc/key-papers/paper-monumental-1-talquetamab-nejm-2022/)
- drugs: [ISB 2001](https://onco.cc/drugs/isb-2001/)
- biomarkers: [GPRC5D expression](https://onco.cc/biomarkers/gprc5d-expression/)

---
JSON: https://onco.cc/api/v1/entities/talquetamab.json